APA (7th ed.) Citation

Liu, W., Huo, G., & Chen, P. (2023). First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: A cost-effectiveness analysis in the United States. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Liu, Wenjie, Gengwei Huo, and Peng Chen. First-line Tremelimumab Plus Durvalumab and Chemotherapy Versus Chemotherapy Alone for Metastatic Non-small Cell Lung Cancer: A Cost-effectiveness Analysis in the United States. Frontiers Media S.A, 2023.

MLA (9th ed.) Citation

Liu, Wenjie, et al. First-line Tremelimumab Plus Durvalumab and Chemotherapy Versus Chemotherapy Alone for Metastatic Non-small Cell Lung Cancer: A Cost-effectiveness Analysis in the United States. Frontiers Media S.A, 2023.